Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma.

Reddy N, Greer JP, Goodman S, Engelhardt B, Oluwole O, Jagasia MH, Savani BN
Bone Marrow Transplant. 2012 47 (10): 1318-20

PMID: 22327132 · PMCID: PMC4845748 · DOI:10.1038/bmt.2012.10

Thirty-five consecutive patients with follicular lymphoma (FL) receiving SCT at our institution between January 2000 and December 2010 were included in this study. At the time of presentation, 30 (86%) had advanced stage disease and 25 (71%) received three or more chemotherapy regimens prior to transplantation. In all, 12 (34%) patients were in complete response pre-SCT following salvage therapy. At the time of analysis (median follow-up 6 years from diagnosis and 4 years from transplantation), 24 patients were alive with an estimated 5-year OS and PFS of 66.5 and 53%, respectively. OS and PFS in patients receiving auto-SCT (91.7%, 73.3%) were superior compared with patients receiving allo-SCT (53.9%, 43%). Our data support early use of auto-SCT in patients with FL and suggest the need to improve allo-SCT outcome. Integrating novel agents in a combined modality approach may improve long-term outcome in FL.

MeSH Terms (14)

Adult Disease-Free Survival Female Follow-Up Studies Humans Lymphoma, Follicular Male Middle Aged Retrospective Studies Stem Cell Transplantation Survival Rate Time Factors Transplantation, Autologous Transplantation, Homologous

Connections (2)

This publication is referenced by other Labnodes entities: